PROCEPT BioRobotics stock posts 18% Q3 revenue growth

Published on 11/05/2026 at 03:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PROCEPT BioRobotics stock reported stronger procedure activity and reaffirmed its 2026 outlook. Losses widened as investment spending increased.

Results strengthen growth outlook

PROCEPT BioRobotics reported third-quarter revenue growth alongside higher U.S. procedure volumes and international sales.
Management reaffirmed its 2026 revenue, procedure-volume, gross-margin and adjusted EBITDA guidance.
The WATER IV trial remains on track to deliver primary endpoint data in the first half of 2027.

PRCT, US74276L1052, Illustration mit AI erstellt.

PROCEPT BioRobotics reported third-quarter 2026 results on Wednesday, November 4, highlighting continued demand for its urology-focused robotic systems. The company said revenue increased 18 percent year over year, while management maintained its full-year outlook.

Revenue rises as procedures expand

According to the Yahoo Finance report carrying the company release, third-quarter revenue reached 98.3 million US dollars for the period ended September 30, 2026. U.S. procedures exceeded 13,400, up about 22 percent from a year earlier, while international revenue rose 32 percent to 12.5 million US dollars.

PROCEPT delivered 62 HYDROS systems in the United States, including 20 replacement systems. Handpiece and consumable revenue increased 21 percent to 53.9 million US dollars, supporting the recurring-revenue element of the installed-base model.

Losses widen despite gross-margin gain

Gross margin improved to 66 percent from 65 percent in the prior-year quarter. Operating expenses rose to 92.5 million US dollars as the company continued spending on personnel, product development, clinical studies and sales programs.

Net loss widened to 26.5 million US dollars from 21.4 million US dollars a year earlier. Adjusted EBITDA was negative 9.8 million US dollars, compared with negative 7.4 million US dollars in the third quarter of 2025.

Guidance remains unchanged

PROCEPT reaffirmed 2026 revenue guidance of 390 million to 410 million US dollars and U.S. procedure guidance of 54,000 to 56,000. Management also maintained its gross-margin outlook of about 65 percent and an adjusted EBITDA loss range of 30 million to 35 million US dollars.

The company said the WATER IV randomized trial comparing Aquablation with radical prostatectomy in prostate cancer remains on track for primary endpoint data in the first half of 2027. The timing gives investors a further clinical milestone to monitor beyond near-term system placements and procedure utilization.

Urology specialist in robotic surgery

PROCEPT BioRobotics is a commercial-stage surgical robotics company based in the United States. It develops, manufactures and sells the image-guided AQUABEAM and HYDROS robotic systems for minimally invasive urologic surgery, initially focused on benign prostatic hyperplasia, according to the company's corporate profile. Compared with broader platforms from Intuitive Surgical, Medtronic and CMR Surgical, PROCEPT occupies a narrower specialty position centered on urology and Aquablation.